A Comparative Study to Evaluate Efficacy and Safety of Daily Dosing versus Alternate-Day Atorvastatin Therapy in Patients with Dyslipidemia

Allen J. Rodrigues, Syed S. Farookh, Laxminarayana Kamath, Raveendra K.R

Abstract


 

 Dyslipidemia is a well-recognized risk factor for the development of diseases associated with atherosclerosis, including coronary artery disease and stroke. Statins are the first choice hypolipidemic drug which are the most effective and best tolerated agents for treating dyslipidemia. Atorvastatin confers an HMG-CoA reductase inhibition up to 20-30 hours which makes it even effective on the next day. The present study is randomized open labeled study done at Victoria Hospital - Bangalore to compare efficacy and safety of daily dosing versus alternate-day atorvastatin therapy in patients with dyslipidemia. A total of 86 patients with dyslipidemia were randomized into 2 groups. Group A received 10 mg of atorvastatin daily (DS) and group B received 10 mg of atorvastatin on alternate day (AS) for six weeks. Among the 86 patients included in the study, mean age of the participants in the AS group was 53.12 ± 10.32 whereas that in the DS group was 52.26 ± 11.13. LDL-C decreased by 25.3% versus 22.4% (CI 0.95, P = 0.35) on daily and alternate-day dosing, respectively. Also 12.5% versus 15% (CI 0.95, P= 0.83) improvement was seen with HDL-C. Both dosage regimens provided reductions in total cholesterol (20.7% versus 20.2%) and triglyceride (20.7% versus 21.2%). There was no statistically significant difference in reduction in lipid parameters between two groups. Adverse effects were found less occurred in alternate day therapy than daily therapy. Gastrointestinal disturbances and myalgia were most commonly reported in both groups. Hence this study concludes alternate-day atorvastatin is as effective as daily atorvastatin in dyslipidemia. 


Keywords


Dyslipidemia; LDL cholesterol; Alternate day atorvastatin

Full Text:

PDF

References


Bersot PT. Drug Therapy for Hypercholesterolemia and Dyslipidemia. In: Goodman and Gilman’s “The Pharmacological basis of Therapeutics In: Brunton LL,. 12th ed. New York. McGraw-Hil; 2010. p. 884–91.

Park K. Epidemiology of chronic non- communicable diseases and conditions. In: Park’s Textbook of Preventive and Social Medicine, In: Park K. 23rd ed. Jabalpur: Bhanot; 2009. p. 365–72.

National cardiovascular disease database (online)(cited 2015 june 11): available from http://www.searo.who.int/india/ topics/cardiovascular_diseases/NCD_ Resources_National_CVD_database- final_report.pdf?ua=1.

Guptha S, Gupta R, Deedwania P, Bhansali A, Maheshwari A, Gupta A, et al. Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: A cross sectional study. Indian Heart Journal. 2014 May;66(3):280–8.

Gupta R, Rao RS, Misra A, Sharma SK. Recent trends in epidemiology of dyslipidemias in India. Indian Heart Journal. 2017 May - Jun;69(3):382-92.

Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK, et al. Prevalence of Dyslipidemia in Urban and Rural India: The ICMR–INDIAB Study. Goel K, editor. PLoS ONE. 2014 May 9;9(5):e96808.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143–421.

Stern RH, Yang BB, Hounslow NJ,MacMahon M, Abel RB, Olson SC. Pharmacodynamics and pharmacokinetic- pharmacodynamic relationships of atorvastatin, an HMG- CoA reductase inhibitor. Journal of Clinical Pharmacology. 2000;40:616–23

Ghia CJ, Panda AS, Khobragade LR, JhaRK, Rambhad GS. Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia. Journal of Clinical and Diagnostic Research. 2014 Mar;8(3):27- 31.

Awad K, Mikhailidis DP, Toth PP, Jones SR, Moriarty P, Lip GYH, et al. Efficacy and Safety of Alternate- Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy. 2017 Aug;31(4):419-31.

Ferrer-García JC, Pérez-Silvestre J, Martínez-Mir I, Herrera-Ballester A. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Acta Diabetologica. 2006 Nov;43(3):75-8.

Pramanik S, Das AK, Chakrabarty M, Bandyopadhyay SK, Ghosh M, Dalai CK. Efficacy of alternate-day versus everyday dosing of atorvastatin. Indian Journal of Pharmacology. 2012 May;44(3):362-5.

Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). American Heart Journal. 2002 Oct;144(4):674-7.

Pattanaik S, Malhotra S, Sharma YP, Pandhi P. Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile. Journal of Cardiovascular Pharmacology. 2012 May;59(5):479-84.

Hadjibabaie M, Gholami K, Khalili H, Khoei SH, Nakhjavani M, Rayati K, et al. Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic Type 2 diabetic patients. Therapy. 2006 Nov;3(6):759–64.

Bijay K, Agarwal PK, Pranjal P, Meghwani MK. Dose alternate day dosing of statin suffice?(A comparative study of O.D to A/D dosing of atorvastatin on hypercholesterolemia ). Journal of Advance Researches in Biological Sciences. 2013;5(1):23–4.

Aghasadeghi K, Zare D. Efficacy of alternate day dosing of atorvastatin. Central European Journal of Medicine. 2008 Apr 10;3(2):163.

Keleş T, Akar Bayram N, Kayhan T, Canbay A, Sahin D, Durmaz T, et al. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. The Anatolian Journal of Cardiology. 2008 Dec;8(6):407-12.

Rader DJ et al. Disorders of lipoprotein metabolism. In: Lango D, Kasper DL, James Jl, Fausi AS, Hauser SL, Loscalzo J. editors. In: Harrison’s principles of internal medicine. 18th ed. New York: McGraw- Hill; 2012. p. 3145–61.

Jacques Genest, Peter Libby. Lipoprotein Disorders and Cardiovascular Disease. In: Brawnwald’s heart disease, A textbook of cardiovascular medicine. 9th ed. Philadelphia: Elsevier saunders; p. 975–94.

Malloy MJ, Kane JP. Agents used in dyslipidemia. In: In:Katzung BG, Trevor AJ editors Basic and Clinical pharmacology. 13th ed. New Delhi: McGraw Hill education private limited; 2012. p. 602–17.

Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M. Efficacy of Alternate-Day Dosing Versus Daily Dosing of Atorvastatin. Journal of Cardiovascular Pharmacology and Therapeutics. 2003 Jun;8(2):123–6.




DOI: https://doi.org/10.15416/pcpr.v6i2.32412

Refbacks

  • There are currently no refbacks.


                                                                         
Pharmacology and Clinical Pharmacy Research is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
 
                                                                      VIEW VISITOR STATS